Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Abstract Background Proprotein convertase subtilisin/kexin 9 (PCSK9) has been proposed as a novel target for coronary artery disease (CAD). Familial hypercholesterolemia (FH) is characterized by high prevalence of CAD and major cardiovascular events (MACEs). However, no data is available on the asso...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2019-11-01
|
| Ráidu: | Journal of Translational Medicine |
| Fáttát: | |
| Liŋkkat: | http://link.springer.com/article/10.1186/s12967-019-2123-9 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|